{"entity":{"id":"nct06939595","kind":"trial","name":"A Study to Compare Effects and Safety of CT-P51 and Keytruda in Patients With Previously Untreated Metastatic Lung Cancer","aka":[],"tldr":"A phase 3 trial of Pembrolizumab in non-small-cell lung cancer, run by Celltrion, active and no longer recruiting.","summary":"A Study to Compare Effects and Safety of CT-P51 and Keytruda in Patients With Previously Untreated Metastatic Lung Cancer is a phase 3 interventional study registered as NCT06939595 by Celltrion, with 225 participants enrolled, started 2025-01-30 and due to reach its primary completion in 2027-02. Interventions recorded: CT-P51 and EU-approved Keytruda.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06939595","url":"https://clinicaltrials.gov/study/NCT06939595"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["pembrolizumab"],"companies":["celltrion"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06939595","phase":"3","setting":"A Double-Blind, Randomized, Active-Controlled, Parallel-Group, Phase 3 Study to Compare Efficacy and Safety of CT-P51 and Keytruda in Combination With Platinum-Pemetrexed Chemotherapy in Patients With Previously Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer","sponsor":"Celltrion","enrolled":225,"outcomes":[]},"route":"/trials/nct06939595/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"company":[{"id":"celltrion","kind":"company","name":"Celltrion","route":"/companies/celltrion/"}]}}